Clinical trials: Pregnancy, High-risk
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Hepatitis B Infection, Congenital Malformation
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia
- Trial name
- NCT03476083
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
- Where
- 7 sites in China
- Volunteers
- 280 people
- Sponsor
- New Discovery LLC
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Superficial Bladder Cancer
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed…
- Trial name
- NCT01687244
- Testing
- INSTILADRIN
- Volunteers
- 40 people
- Sponsor
- FKD Therapies Oy
Bladder Cancer
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.
- Trial name
- NCT05704244
- Testing
- FE 999326
- Where
- 24 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Delayed Graft Function, End Stage Renal Disease
Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Conditions
- Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
- Trial name
- NCT07020832
- Testing
- Pegcetacoplan
- Where
- Brazil
- Sponsor
- Apellis Pharmaceuticals, Inc.
Secondary Hyperparathyroidism, End Stage Renal Disease
Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism
Secondary hyperparathyroidism (sHPT) is common in patients with chronic kidney disease (CKD), including those who are undergoing long-term haemodialysis treatment.
- Conditions
- Secondary Hyperparathyroidism, End Stage Renal Disease, Parathyroid Hyperplasia
- Trial name
- NCT01421407
- Testing
- Ultrasonic ablation device
- Where
- 3 sites in Italy, Spain
- Sponsor
- Theraclion
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Respiratory Syncytial Virus Infection, Premature Birth
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
- Trial name
- NCT01006629
- Testing
- palivizumab
- Where
- 19 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
Carcinoma, Neoplasia; Intraepithelial, Cervix
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Phase II clinical trial, monocentric, not controlled, in patients with high grade cervical intraepithelial lesions. A total of 62 patients with a diagnosis of CIN II, III or carcinoma in situ will be included.
- Conditions
- Carcinoma, Neoplasia; Intraepithelial, Cervix, Glandular Neoplasms, Epithelial Neoplasm
- Trial name
- NCT03549273
- Testing
- Glizigen® + Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 62 people
- Sponsor
- Catalysis SL
Solid Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
- Trial name
- NCT06161025
- Testing
- R-DXd, Paclitaxel, Topotecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 860 people
- Sponsor
- Daiichi Sankyo
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Chronic Kidney Disease, Arterial Hypertension
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure.
- Trial name
- NCT06428825
- Testing
- BAY3283142
- Where
- 2 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and…
- Trial name
- NCT01847274
- Testing
- Active comparator: Niraparib
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 596 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Fallopian Tube Cancer, Ovarian Cancer
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer
- Trial name
- nCYT (NCT03593681)
- Testing
- Hysteroscopic cell sampling of the fallopian tube
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Epithelial Ovarian Cancer
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be…
- Trial name
- WoO (NCT04644289)
- Testing
- olaparib, durvalumab
- Where
- 6 sites in Germany
- Volunteers
- 60 people
- Sponsor
- AGO Research GmbH
Uterine Cervical Neoplasms, Cervix Intraepithelial Neoplasia
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix…
- Trial name
- NCT00989443
- Testing
- Cidofovir gel
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Mithra Pharmaceuticals